Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo!...
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a =2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p Zenkuda also demonstrated superiority to sham with an 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001) and with a =3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p Zenkuda demonstrated strong efficacy independent of concomitant GLP-1 receptor agonist use. In Zenkuda-treated patients, the proportion achieving a =2-step improvement in DRSS was 60.0% among those using GLP-1 medications versus 64.3% among those not using GLP-1 medications, supporting Zenkuda's efficacy profile in a real-world diabetic population. Zenkuda demonstrated favorable safety and was well tolerated in the study with a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]Seeking Alpha
- Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.MarketBeat
- Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamPR Newswire
KOD
Earnings
- 11/13/25 - Miss
KOD
Sec Filings
- 3/27/26 - Form 4
- 3/27/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- KOD's page on the SEC website